Medical Device Firm Founded by Lumens Founder Seeks Liquidation

Filterlex Medical Ltd., a medical device company, has filed a request with the Haifa District Court to initiate liquidation proceedings due to accumulating debts of 1.3 million shekels. The company's shareholder and director is Dr. Shimon Eckhouse, the founder of Lumens. According to the petition filed by attorney Achiyad Harel on behalf of the company, Filterlex Medical has ceased all operations, has no income, no employees, and no source of funding, including equity, credit, or grants.

The startup, which focused on cardiology equipment and developed a system to prevent embolisms during aortic valve replacement via catheterization, has reportedly never generated revenue. Its operations were funded by investor capital and research and development grants, a common funding model for medical startups in the development phase. The company's survival depended entirely on its ability to secure subsequent funding rounds, as stated in the petition.

Despite hopes that clinical data would demonstrate the product's benefits, these hopes were dashed. While the company progressed as expected, with its product undergoing clinical trials in Israel and receiving FDA approval in February 2025 to begin trials for a second-generation product in the U.S., the publication of results from a large-scale study on a competing product by Boston Scientific, named Sentinel, significantly impacted Filterlex. The study indicated minimal benefit for products like the one Filterlex developed, raising substantial questions about the clinical need and commercial potential for stroke prevention during cardiac catheterization.

Following these findings, a board meeting determined that the chances of raising capital were low. However, the board decided to freeze, rather than close, the company's operations until the commercial landscape became clearer, a decision reflected in the fact that the CEO has been working without salary since June 2025, a period exceeding two years. The company's debts amount to 1.3 million shekels, with the majority owed to the European Union. Attempts to sell the company's intellectual property were unsuccessful, leading to the decision to proceed with liquidation.

The petition attributes the company's financial difficulties to two main factors: the publication of external clinical findings that undermined the clinical and commercial justification for its field, thus preventing further funding, and the absence of any alternative funding or buyer after exhausting all available options.